Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01821768
NCT01821768TerminatedNot Applicable

A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound

Washington University School of Medicine1 site in 1 country69 target enrollmentStarted: April 4, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
69
Locations
1
Primary Endpoint
Regional (axillary) recurrence
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This randomized clinical trial studies two different tests that are currently being used to detect the spread of breast cancer to the lymph nodes under the arm in candidates for breast conservation therapy. The two tests are sentinel lymph node biopsy (SLNB) and axillary ultrasound. The current standard of care is sentinel lymph node biopsy, which is a surgical procedure. Axillary ultrasound (AUS) may be just as good as SLNB for detecting the spread of cancer but without the surgical risks.

Detailed Description

In this prospective randomized non-inferiority study we aim to determine the utility of axillary ultrasound (AUS) as a pre-operative staging modality for patients with clinically node-negative invasive breast cancer with the hope that it will be a minimally invasive replacement for SLNB.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient must be female.
  • •Patient must be at least 18 years of age.
  • •Patient's clinical stage must be documented as tumor size less than 5 cm, with no palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0). For patients who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be used.
  • •Patient must have a negative (normal) axillary ultrasound performed at Siteman Cancer Center. Lymph nodes will be evaluated based on morphologic features. AUS wil be considered positive (abnormal)if lymph nodes are noted to be completely hypoechoic (absent hilum) or have focal hypoechoic cortical thickening/lobulation greater than 4 mm.
  • •Patient must have a tissue diagnosis of invasive breast carcinoma
  • •Patient must have Eastern Cooperative Oncology Group (ECOG) status </= 2, as documented in patient's medical record.
  • •Patient must be available for follow-up.
  • •A patient with a history of previous malignancy is eligible for this study as long as the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided that the following criteria are met (1) The patient has undergone potentially curative therapy for all prior malignancies; (2) There has been no evidence of any prior malignancies for at least five years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone); and (3) The patient is deemed by their treating physician to be at low risks for recurrence from prior malignancies.
  • •Patient, or the patient's legally acceptable representative, must provide a signed and dated written informed consent prior to registration and any study-related procedures.
  • •Patient must provide written authorization to allow the use and disclosure of their protected health information. NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration.
  • •Patient must be a candidate for sentinel lymph node biopsy (SLNB).

Exclusion Criteria

  • •Patient in lactating (breast-feeding) or pregnant.
  • •Patient has concurrent invasive bilateral breast malignancies or multicentric disease.
  • •Patient has had previous ipsilateral axillary surgery such as excisional biopsy of lymph nodes(s), treatment of hidradenitis.
  • •Patient is considered poor candidate surgical candidate due to non-malignant systemic disease.

Arms & Interventions

Arm 1: No sentinal lymph node biopsy

No Intervention

Patients will receive no additional axillary surgery which is experimental.

Arm 2: Sentinel lymph node biopsy

Active Comparator

Patients will receive standard of care sentinel lymph node biopsy

Intervention: Sentinel Lymph Node Biopsy (Procedure)

Outcomes

Primary Outcomes

Regional (axillary) recurrence

Time Frame: 5 years from date of surgery

The distributions of the primary endpoints and complications across two arms will be summarized using contingency tables and compared by 2-sample Chi-square test or Fisher's exact test.

Secondary Outcomes

  • Disease free survival Arm 1 versus Arm 2.(At least 5 years form date of surgery to date of any disease recurrence.)
  • Overall survival Arm 1 versus Arm 2(5 years from date of surgery)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium CancerEndometrial Cancer
NCT06656949Qilu Hospital of Shandong University42
Recruiting
Not Applicable
Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial CancerEndometrial Cancer
NCT04845828Asan Medical Center810
Completed
Phase 4
Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerBreast Cancer
NCT02287675Kettering Health Network40
Recruiting
Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerHard Palate Squamous Cell CarcinomaLip Squamous Cell CarcinomaStage I Lip and Oral Cavity Cancer AJCC v8Tongue Squamous Cell CarcinomaLower Alveolar Ridge Squamous Cell CarcinomaRetromolar Trigone Squamous Cell CarcinomaStage II Lip and Oral Cavity Cancer AJCC v8Buccal Mucosa Squamous Cell CarcinomaFloor of Mouth Squamous Cell CarcinomaGingival Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaUpper Alveolar Ridge Squamous Cell Carcinoma
NCT04333537NRG Oncology686
Completed
Not Applicable
Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast CancerBreast Cancer
NCT00293865Institut Cancerologie de l'Ouest203